Medtronic to announce Q4 results amidst pacemaker crisis
Medtronic (NYSE: MDT) is scheduled to report fourth-quarter 2019 financial results on Thursday, May 23, before the regular trading hours....
Health Care
Bio-Path’s stock tanks as company delivers loss for Q1
Bio-Path Holdings Inc.’s (NASDAQ: BPTH) shares were down 3.2% in morning hours on Thursday after the company reported its first...
Titan Pharmaceuticals posts wider-than-expected Q1 loss
Titan Pharmaceuticals (TTNP) reported a wider loss in the first quarter of 2019 due to lower revenues and higher operating...
Johnson & Johnson set to revitalize pharma biz; eyes ‘above-market’ growth
Drug maker Johnson & Johnson (NYSE: JNJ) is all set to embark on an extensive program to strengthen the product...
Aurora Cannabis’ net loss widens in Q3
Like last quarter, Canadian-based cannabis producer Aurora Cannabis (NYSE: ACB) delayed its third-quarter earnings today. The company reported a loss...
Aurinia Pharmaceuticals loss narrowed in Q1; AURORA trial on track
Aurinia Pharmaceuticals (NASDAQ:AUPH / TSX:AUP) narrowed its loss in the first quarter. Post the Q1 results, stock rose 2% in...
Tilray Q1 loss widens, meets estimates
Tilray (TLRY) reported a wider loss in the first quarter of 2019 due to higher operating costs and expenses. The...
Earnings: Agilent stock falls on Q2 earnings miss, weak guidance
Earnings of Agilent Technologies (Nasdaq: A), which manufactures instruments used in medical laboratories, increased in the second quarter but missed...
Solid Biosciences tumbles 38% to hit historic low
Shares of Solid Biosciences Inc. (NASDAQ: SLDB) opened 38% lower on Tuesday after the company said in its first-quarter results...
Earnings: Catabasis Q1 loss narrows on lower expenses, beats estimates
Catabasis Pharmaceuticals (Nasdaq: CATB) reported a narrower net loss for the first quarter of 2019. The improvement in the bottom...
InspireMD Q1 revenues plunge on third-party equipment failure
Israel-based medical device company InspireMD (NYSE: NSPR) reported a first-quarter loss of $3.82 per share, much wider than the loss...
CorMedix reports upbeat Q1 results; provides business update
Biopharmaceutical company CorMedix (CRMD) reported its first quarter 2019 results after the bell today. CorMedix recorded a net loss of...
Catalyst Pharmaceuticals’ Q1 results beat estimates
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported first-quarter 2019 revenue and earnings that surpassed analysts’ expectations. Shares climbed around 4% in premarket...
Aurora Cannabis Q3 earnings: What’s in the cards?
Canadian-based cannabis producer Aurora Cannabis (NYSE: ACB) is slated to report its third-quarter results on May 14 after the bell...
Earnings preview: Agilent braces for an upbeat Q2 amid stable demand
Agilent Technologies (NYSE: A), which makes analytical instruments for laboratories, will be publishing its second-quarter financial results Tuesday after the...
ESSA Pharma posts narrower loss in Q2
ESSA Pharma Inc. (EPIX) reported a narrower loss in the second quarter of 2019 helped by lower research and development...
Earnings: Ocular Therapeutix Q1 loss widens on higher R&D expenses
Biopharmaceutical firm Ocular Therapeutix (Nasdaq: OCUL) reported a wider net loss for the first quarter – despite an increase in...
Corbus Pharma’s Q1 results fall short of expectations
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) missed market expectations on revenue and earnings for the first quarter of 2019. The...
Cronos Group starts off fiscal 2019 with a profit in Q1
In the first quarter of 2019, Cronos Group (NASDAQ: CRON) more-than-doubled its revenues to C$6.5 million, primarily driven by the launch...
Portola’s stock crashes 12% despite Q1 results beat
Shares of Portola Pharmaceuticals (NASDAQ: PTLA) plummeted 12.7% in morning trade on Wednesday despite the company achieving better-than-expected revenue and...
Intercept Pharmaceuticals reports mixed Q1 results
Intercept Pharmaceuticals (NASDAQ: ICPT) reported wider-than-expected losses in the first quarter of 2019, primarily due to higher R&D expenses related...